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Abstract: International cardiovascular society recommendations to return to sports activities following
acute myocarditis are based on expert consensus in the absence of prospective studies. We prospectively
enrolled 30 patients with newly diagnosed myocarditis based on clinical parameters, laboratory measure-
ments and cardiac magnetic resonance imaging with mildly reduced or preserved left ventricular ejection
fraction (LVEF) with a follow-up of 12 months. Cessation of physical activity was recommended for 3
months. The average age was 35 (19-80) years with 73% male patients. One case of non-sustained ven-
tricular tachycardia was recorded during 48-h-Holter electrocardiogram. Except for this case, all patients
were allowed to resume physical exercise after 3 months. At 6- (n = 26) and 12-month (n = 19) follow-up
neither cardiac events nor worsening LVEF were recorded. The risk of cardiac events at 1 year after
diagnosis of myocarditis appears to be low after resumption of exercise after 3 months among patients
who recover from acute myocarditis.
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Abstract
International cardiovascular society recommendations to return to sports activities following acute myocarditis are based on
expert consensus in the absence of prospective studies. We prospectively enrolled 30 patients with newly diagnosed myocarditis
based on clinical parameters, laboratory measurements and cardiac magnetic resonance imaging with mildly reduced or pre-
served left ventricular ejection fraction (LVEF) with a follow-up of 12 months. Cessation of physical activity was recommended
for 3 months. The average age was 35 (19–80) years with 73% male patients. One case of non-sustained ventricular tachycardia
was recorded during 48-h-Holter electrocardiogram. Except for this case, all patients were allowed to resume physical exercise
after 3 months. At 6- (n = 26) and 12-month (n = 19) follow-up neither cardiac events nor worsening LVEF were recorded. The
risk of cardiac events at 1 year after diagnosis of myocarditis appears to be low after resumption of exercise after 3 months among
patients who recover from acute myocarditis.
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CMR cardiac magnetic resonance imaging
ECG electrocardiogram
LGE late gadolinium enhancement
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NT-proBNP n terminal pro brain natriuretic peptide
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LVEF left ventricular ejection fraction
CMR cardiac magnetic resonance imaging
Athletes appear to be at special risk for sudden cardiac death
following acute myocarditis, possibly because intense physi-
cal exercise increases viral replication and suppresses the im-
mune system. In turn, this may lead to enhanced susceptibility
for upper respiratory infections [1]. It has been hypothesized
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that the inflammatory process accompanying a virus-associat-
ed myocarditis also involves conduction tissue in ways that
can lead to potentially lethal arrhythmias [2]. As a result of
these findings, physical activity is contraindicated for a period
of 3 to 6 months after a diagnosis of myocarditis [3, 4].
Importantly, the recommendation to refrain from physical ac-
tivity following an episode of virus-associated myocarditis
has not been critically examined and the optimal duration of
exercise cessation remains unknown.
To address the question of exercise following myocarditis, we
prospectively evaluated the safety of early resumption of exercise
3 months following diagnosis with myocarditis in asymptomatic
patients without arrhythmias on 48-h-Holter electrocardiogram
(ECG) monitoring or stress testing with normal or recovered left
ventricular ejection fraction (LVEF). Outcomes included adverse
cardiovascular events, defined as persistent or malignant arrhyth-
mias, worsening LVEF, hospitalizations for heart failure, and
death after resumption of exercise at 3-month until 12-month
follow-up.
Myocarditis was defined according to ESC diagnostic
criteria, including: Clinical presentation with dyspnea, chest
pain, palpitations, elevated high sensitivity troponin T (TnT-
hs) (> 14 ng/l), angiographic exclusion of obstructive coronary
artery disease (grade of stenosis <50%), and characteristic fea-
tures on cardiac magnetic resonance imaging (CMR) [5].
Subjects were advised to avoid strenuous exercise for 3 months.
In order to minimize the risk for adverse events in this first
prospective trial, patients with severely reduced LVEF
(<35%) at the time of enrolment were not included in this study.
At 3, 6 and 12 months follow-up subjects received a car-
diovascular examination including history and physical exam,
laboratory testing of C-reactive protein (CRP; normal range <
5 mg/l), TnT-hs (normal range < 14 ng/l), myoglobin (Mb;
normal range 28–72 μg/l), creatine kinase (CK) (normal
range < 190 U/l), N-Terminal B-type natriuretic peptide (NT-
proBNP) (normal range < 125 pg/ml), leukocytes (Lc; normal
range 3–9.6 G/l), resting 12-lead ECG, 48-h-Holter ECG, ex-
ercise stress testing with ramp protocol, and echocardiogra-
phy. CMR was repeated as part of the 3 months follow-up.
Table 1 Baseline characteristics of all patients with myocarditis.
Baseline characteristics all cases of myocarditis Value (n = 30)
Male Sex, n (%) 22 (73)
Median age (IQR) 32 (22–42)
Mean BMI kg/m2, (±SD) 26.7 (±4.6)
aHTN, n (%) 3 (10)
HLD, n (%) 3 (10)
DM, n (%) 1 (3)
History of smoking, n (%) 10 (33)
Abbreviations: aHTN = arterial hypertension; BMI = body mass index;
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Fig. 1 Flowchart of our
population
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Our population consisted of 30 patients with a median
age of 35 years (range: 19–80 years) of whom 8 (27%)
were women and 22 (73%) were men. Baseline character-
istics are presented in Table 1. Due to loss of follow-up,
26 patients presented for 6 months follow-up and 19 pa-
tients presented for their 12-month visit (Fig. 1). All pa-
tients who did not present for evaluation after 6 or
12 months were contacted by telephone call. Overall,
no cardiac events were recorded during the time period
of 12 months after symptom onset.
Initially, all patients showed patchy or diffuse midwall late
gadolinium enhancement (LGE) patterns. In 16 (53%) cases
additional edema was present in T2 weighted images.
After 3 months visually assessed extent of LGE decreased
in all patients. No edema was detected on repeat CMRs and 7
(24%) patients showed complete remission of LGE.
At presentation, the averaged LVEF was 58% (± 7.4).
Three patients revealed a mid-range reduced LVEF. During
the follow-up, one remained stable while others normalized.
During follow-up stress testing, neither significant ECG
changes nor pathological symptoms were provoked.
After 3 months, 48-h-Holter ECG showed episodes of non-
sustained ventricular tachycardia in one patient. As a conse-
quence, physical exercise was discouraged in this case until
further investigations at 6-month follow-up. This 19-year-old
man initially presented with severe dyspnoea NYHA III; how-
ever, only mild angina-like symptoms were present. The
LVEF was stable with elevated CRP 12 mg/l, TnT-hs 276
ng/l, Mb 41 µg/l, CK 213 U/l, and normal NT-proBNP 158
ng/l and Lc 6.95 G/l. After 6 months, all elevated biomarkers
normalized and 48-h-Holter ECG as well stress testing
showed no signs of arrhythmias. On CMR, initial LGE de-
clined after 3 months and edema on T2-weighted images dis-
appeared. Results from repeated laboratory testing are demon-
strated in Table 2.
In a first attempt we evaluated early resumption of physical
activity after 3 months in a small cohort of patients who re-
cover from acute myocarditis. This allowed us to identify
patients without clinical abnormalities such as increasing
levels of TnT-hs, arrhythmias in resting 12-lead ECG or 48-
h-Holter ECG, worsening of maximum power on exercise
stress testing or worsening LVEF as potentially good candi-
dates for early resumptions of exercise.
Due to the small sample size, the statistical power of this
study is limited. Given the numerous beneficial effects of
physical activity, further research is necessary to determine
the right timing for resumption of exercise after the onset of
myocarditis.
Table 2 Overall findings at time of onset, 3 and 6-month follow-up.
Baseline characteristics all cases of myocarditis Time of symptom onset 3-month follow-up 6-month follow-up 12-month follow-up P Value
CMR/Echocardiography n = 30 n = 30 n = 26 n = 19
Mean LVEF (±SD) 58 (±7.44) 59 (±6) 59.4 (±4.8) 58 (±5.3) NS
Resting ECG n = 30 n = 30 n = 26 n = 19
Number of malignant arrhythmias 0 1 0 0 NS
Number of benign arrhythmias 8 6 4 4 NS
48-h-Holter ECG n = 0 n = 30 n = 26 n = 19
Number of malignant arrhythmias / 1 0 0 NS
Number of benign arrhythmias / 6 6 4 NS
Median APC/QRS % (IQR) / 0.0172 (0.008–0-047) 0.036 (±0.055%) 0.034 (0.002–0.06 NS
Median PVC/QRS % (IQR) / 0.008 (0–0.0029) 0. 16% (±0.782%) 0.0026 (0–0.02) NS
Exercise stress test n = 0 n = 29 n = 25 n = 19
Mean performance, watts (±SD) / 190 (±67) 195 (±75) 206 (±75) NS
Mean % of predicted maximum watt / 95% (±27) 98 (±26) 105 (±26) NS
Number of malignant arrhythmias / 0 0 0 NS
Laboratory results (median) n = 30 n = 30 n = 26 n = 19
Mb, ng/l (IQR) 32 (0–111) 27 (0–40) 22.7 (±31.1) 27 (0–43) 0.011
TnT-hs, ng/l (IQR) 350 (88–1104) 2.5 (0–7) 4.4 (±7.5) 0 (0–7) <0.001
CK, U/l (IQR) 238 (128–587) 97 (66–156) 130.3 (±63) 119 (75–193) 0.001
NT-proBNP, ng/l (IQR) 251 (45–676) 30 (11–44) 63 (±84) 38 (13–121) 0.05
CRP, mg/l (IQR) 21 (3–66) 0.7 (0.4–2.6) 1.6 (±1.8) 0.9 (0.5–1.6) <0.001
Lc, G/L (IQR) 7 (6–9) 6.8 (5.9–7.2) 5.9 (±2.3) 6 (5.6–7.6) NS
Abbreviations: CMR = cardiac magnetic resonance imaging; SD = standard deviation; ECG = electrocardiogram; APC = atrial premature contraction;
TnT-hs = high sensitivity troponin T, CK= creatine kinase; CRP = C-reactive protein; Lc = leukocytes; LVEF = left ventricular ejection fraction; Mb =
myoglobin; NT-proBNP =NT-pro brain natriuretic peptide; NS = not significant; IQR = interquartile range; PVC = premature ventricular contraction
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